Czechia· CZ-0255583

BREYANZI

A lisocabtagene maraleucel product containing lisocabtagene maraleucel, registered in Czechia by Bristol-Myers Squibb Pharma EEIG, Dublin. The same ATC class is registered in 12 of our 19 countries.

ATC L01XL08

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedBREYANZIATCL01XL08REGISTER NO.CZ-0255583PACKS LISTED0CHECKEDSeptember 28, 2026

Where it is registered

Lisocabtagene maraleucel is registered in 12 of 19 countries.

Countries holding a registration under ATC L01XL08 (lisocabtagene maraleucel), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 8 of them publish a price we can compare per daily dose

Lisocabtagene maraleucel · ATC L01XL08

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
LISOCABTAGENE MARALEUCEL
Manufacturer
Bristol-Myers Squibb Pharma EEIG, Dublin
Country
Czechia (CZ)
ATC code
L01XL08
ATC class
Lisocabtagene maraleucel
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

37 interactions on record for lisocabtagene maraleucel.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Lisocabtagene maraleucel · interactions on record

37 records

  • 21 severe
  • 16 moderate

Most severe, free to view

  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • NatalizumabL04AA23severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c9685ce4-4693-4358-aa2e-49dbff36fdaf
GET /v1/drugs/c9685ce4-4693-4358-aa2e-49dbff36fdaf?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INF DIS",
  "source": "sukl",
  "strength": null,
  "pack_size": "1-4X4,6ML+1-4X4,6ML",
  "substance": "LISOCABTAGENE MARALEUCEL",
  "cz_kod_sukl": "0255583",
  "product_type": "AD/GCM",
  "substance_codes": "21951,21951",
  "registration_state": "R",
  "registration_number": "EU/1/22/1631/001"
}

See everything about lisocabtagene maraleucel.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.